CORD-19:35349bb1fc9290338907b7d7f104c9db3951163b / 28328-28579 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/35349bb1fc9290338907b7d7f104c9db3951163b","sourcedb":"CORD-19","sourceid":"35349bb1fc9290338907b7d7f104c9db3951163b","text":"In conclusion, toceranib elicited weaker reversal properties on pulmonary arterial remodeling and RVH, and therefore, a low dose of toceranib in comparison with sorafenib may not be a promising therapeutic agent for cardiopulmonary remodeling and PAH.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T194","span":{"begin":0,"end":251},"obj":"Sentence"},{"id":"T29318","span":{"begin":0,"end":251},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T194","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T29318","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T57","span":{"begin":64,"end":82},"obj":"Body_part"}],"attributes":[{"id":"A57","pred":"uberon_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/UBERON_0002012"},{"subj":"T57","pred":"source","obj":"CORD-19-PD-UBERON"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T128","span":{"begin":247,"end":250},"obj":"Disease"},{"id":"T124","span":{"begin":247,"end":250},"obj":"Disease"}],"attributes":[{"id":"A128","pred":"mondo_id","subj":"T128","obj":"http://purl.obolibrary.org/obo/MONDO_0015924"},{"id":"A93669","pred":"mondo_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/MONDO_0015924"},{"subj":"T128","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T124","pred":"source","obj":"CORD-19-PD-MONDO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#bfec93","default":true},{"id":"CORD-19-PD-UBERON","color":"#ec93d9"},{"id":"CORD-19-PD-MONDO","color":"#93ece5"}]}]}}